原发性纵隔B细胞淋巴瘤的生物学与治疗:现状与未来方向
原发性纵隔B细胞淋巴瘤(PMBCL)与结节硬化型经典霍奇金淋巴瘤密切相关,诊断常因特征重叠而困难。NF-κB和JAK-STAT通路特征性失调,肿瘤微环境通过多种策略逃避免疫杀伤。R-CHOP和DA-EPOCH-R为最常见一线免疫化疗方案,治疗结束PET扫描为推荐影像模态并正被评估用于放疗分层。复发/难治疾病预后较差,新型靶向异常信号和免疫逃逸的疗法正在开发中。
要点
- PMBCL与结节硬化型经典霍奇金淋巴瘤密切相关,常规诊断范式因特征重叠而具挑战性。
- NF-κB和JAK-STAT通路特征性失调,后者参与宿主免疫逃逸。
- R-CHOP和DA-EPOCH-R为最常见一线免疫化疗方案,治疗结束PET扫描为推荐影像模态。
核心结论
- PMBCL与结节硬化型经典霍奇金淋巴瘤密切相关,常规诊断范式因特征重叠而具挑战性,可靠且适用于常规诊断实验室的诊断和预后生物标志物在很大程度上缺乏。
- NF-κB和JAK-STAT信号通路在PMBCL中特征性失调,参与疾病发病机制的多个方面,其中JAK-STAT通路参与宿主免疫逃逸。
- 肿瘤微环境被PMBCL肿瘤操控以逃避T细胞介导的破坏,策略包括肿瘤细胞抗原性丧失、T细胞耗竭和抑制性T调节细胞激活。
- R-CHOP和DA-EPOCH-R是最常见的一线免疫化疗方案,治疗结束PET扫描是推荐的影像模态,并正在被评估用于对患者进行放疗分层。
- 复发/难治性疾病尽管接受挽救性免疫化疗和后续自体干细胞移植,结局仍相对较差,因此针对异常细胞信号和免疫逃逸的新型疗法正在开发中。
研究设计与样本
- 综述;检索范围原文未报告。
主要发现
- PMBCL与结节硬化型经典霍奇金淋巴瘤密切相关,常规临床、形态学和免疫表型诊断范式因与其他B细胞淋巴瘤特征重叠而具挑战性。
- NF-κB和JAK-STAT信号通路在PMBCL中特征性失调,参与疾病发病机制的多个方面,JAK-STAT通路参与宿主免疫逃逸。
- 肿瘤微环境被PMBCL肿瘤操控以逃避T细胞介导的破坏,策略包括肿瘤细胞抗原性丧失、T细胞耗竭和抑制性T调节细胞激活。
- R-CHOP和DA-EPOCH-R是最常见的一线免疫化疗方案。
- 治疗结束PET扫描是推荐的影像模态,并正在被评估用于对患者进行放疗分层;复发/难治性疾病尽管接受挽救性免疫化疗和后续自体干细胞移植,结局仍相对较差,新型疗法正在开发中。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Primary mediastinal B-cell lymphoma (PMBCL) is a distinct disease closely related to classical nodular sclerosing Hodgkin lymphoma. Conventional diagnostic paradigms utilising clinical, morphological and immunophenotypical features can be challenging due to overlapping features with other B-cell lymphomas. Reliable diagnostic and prognostic biomarkers that are applicable to the conventional diagnostic laboratory are largely lacking. Nuclear factor kappa B (NF-κB) and Janus kinase/signal transducers and activators of transcription (JAK-STAT) signalling pathways are characteristically dysregulated in PMBCL and implicated in several aspects of disease pathogenesis, and the latter pathway in host immune evasion. The tumour microenvironment is manipulated by PMBCL tumours to avoid T-cell mediated destruction via strategies that include loss of tumour cell antigenicity, T-cell exhaustion and activation of suppressive T-regulatory cells. R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone) and DA-EPOCH-R (dose-adjusted etoposide, prednisolone, vincristine, cyclophosphamide, doxorubicin, rituximab) are the most common first-line immunochemotherapy regimens. End of treatment positron emission tomography scans are the recommended imaging modality and are being evaluated to stratify patients for radiotherapy. Relapsed/refractory disease has a relatively poor outcome despite salvage immunochemotherapy and subsequent autologous stem cell transplantation. Novel therapies are therefore being developed for treatment-resistant disease, targeting aberrant cellular signalling and immune evasion.
引用
- Lees C, Keane C, Gandhi MK, et al. Biology and therapy of primary mediastinal B-cell lymphoma: current status and future directions. Br J Haematol. 2019. PMID: 30740662. doi:10.1111/bjh.15778
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。